Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.

Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D, GERICO&UCBG/Unicancer

Open source

DOI: 10.1016/s0140-6736(25)00832-3
Published: 2025 Aug 2
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-00832-3,
  title = {Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.},
  author = {Brain E and Mir O and Bourbouloux E and Rigal O and Ferrero JM and Kirscher S and Allouache D and D'Hondt V and Savoye AM and Durando X and Duhoux FP and Venat-Bouvet L and Blot E and Canon JL and Rollot-Trad F and Bonnefoi H and Roque T and Lemonnier J and Latouche A and Henriques J and Lacroix-Triki M and Vernerey D and GERICO\&UCBG/Unicancer},
  year = {2025},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(25)00832-3},
  url = {https://doi.org/10.1016/s0140-6736(25)00832-3}
}

RIS

TY  - JOUR
TI  - Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
AU  - Brain E
AU  - Mir O
AU  - Bourbouloux E
AU  - Rigal O
AU  - Ferrero JM
AU  - Kirscher S
AU  - Allouache D
AU  - D'Hondt V
AU  - Savoye AM
AU  - Durando X
AU  - Duhoux FP
AU  - Venat-Bouvet L
AU  - Blot E
AU  - Canon JL
AU  - Rollot-Trad F
AU  - Bonnefoi H
AU  - Roque T
AU  - Lemonnier J
AU  - Latouche A
AU  - Henriques J
AU  - Lacroix-Triki M
AU  - Vernerey D
AU  - GERICO&UCBG/Unicancer
PY  - 2025
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(25)00832-3
UR  - https://doi.org/10.1016/s0140-6736(25)00832-3
ER  -

APA

E, B., O, M., E, B., O, R., JM, F., S, K., D, A., V, D., AM, S., X, D., FP, D., L, V., E, B., JL, C., F, R., H, B., T, R., J, L., A, L., J, H., M, L., D, V., & GERICO&UCBG/Unicancer (2025). Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)00832-3

Source records

pubmed · retrieved 2026-09-26T04:23:16.286Z